NDAINHALATIONGAS
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HELIUM, USP (helium) by Advanced Solutions Life Sciences. Approved for asthma, obesity, metabolic syndrome and 1 more indications. First approved in 2020.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELIUM, USP is an inhaled gas product approved in June 2020 for asthma, obesity, metabolic syndrome, and aortic valve stenosis. The product operates through inhalation as a gaseous dosage form with no defined pharmacologic mechanism of action documented. It is currently in peak lifecycle stage under sponsorship by Advanced Solutions Life Sciences.
Peak
Product is at peak commercial stage with competitive pressure at 30%, indicating stable market positioning and ongoing team resource allocation for market maintenance and optimization.
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.